| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30085618 | HIV | ENSG00000007171.19 | protein_coding | NOS2 | No | No | 4843 | P35228 |
| TVIS44042313 | HTLV-1 | ENSG00000007171.19 | protein_coding | NOS2 | No | No | 4843 | P35228 |
| TVIS44042312 | HTLV-1 | ENSG00000007171.19 | protein_coding | NOS2 | No | No | 4843 | P35228 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NOS2 |
|---|---|
| DrugBank ID | DB00125 |
| Drug Name | Arginine |
| Target ID | BE0000005 |
| UniProt ID | P35228 |
| Regulation Type | |
| PubMed IDs | 16778961; 17362916; 17363779; 17340133; 17513447 |
| Citations | Cui YY, Tang CS, Geng B: [Restraint stress down-regulates L-Arg/NOS/NO pathway of platelet and aortic intima in rats]. Beijing Da Xue Xue Bao. 2006 Jun 18;38(3):231-5.@@Devan BD, Pistell PJ, Daffin LW Jr, Nelson CM, Duffy KB, Bowker JL, Bharati IS, Sierra-Mercado D, Spangler EL, Ingram DK: Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine methyl ester. Eur J Pharmacol. 2007 Jun 1;563(1-3):134-40. Epub 2007 Feb 17.@@Rotoli BM, Dall'asta V, Barilli A, D'Ippolito R, Tipa A, Olivieri D, Gazzola GC, Bussolati O: Alveolar macrophages from normal subjects lack the NOS-related system y+ for arginine transport. Am J Respir Cell Mol Biol. 2007 Jul;37(1):105-12. Epub 2007 Mar 15.@@Kagemann G, Sies H, Schnorr O: Limited availability of L-arginine increases DNA-binding activity of NF-kappaB and contributes to regulation of iNOS expression. J Mol Med (Berl). 2007 Jul;85(7):723-32. Epub 2007 Mar 6.@@Popovic PJ, Zeh HJ 3rd, Ochoa JB: Arginine and immunity. J Nutr. 2007 Jun;137(6 Suppl 2):1681S-1686S. |
| Groups | Investigational; Nutraceutical |
| Direct Classification | L-alpha-amino acids |
| SMILES | N[C@@H](CCCNC(N)=N)C(O)=O |
| Pathways | Citrullinemia Type I; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Argininemia; Hyperornithinemia with Gyrate Atrophy (HOGA); Canavan Disease; Hypoacetylaspartia; Hyperprolinemia Type II; 3-Phosphoglycerate Dehydrogenase Deficiency; Non-Ketotic Hyperglycinemia; Argininosuccinic Aciduria; L-Arginine:Glycine Amidinotransferase Deficiency; Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Prolidase Deficiency (PD); Glycine and Serine Metabolism; Hyperglycinemia, Non-Ketotic; Dimethylglycine Dehydrogenase Deficiency; Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency; Carbamoyl Phosphate Synthetase Deficiency; Ornithine Aminotransferase Deficiency (OAT Deficiency); Hyperprolinemia Type I; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Aspartate Metabolism; Nitric Oxide Signaling Pathway; Arginine and Proline Metabolism; Ornithine Transcarbamylase Deficiency (OTC Deficiency); Prolinemia Type II; Urea Cycle; Sarcosinemia |
| PharmGKB | PA448478 |
| ChEMBL | CHEMBL1485 |
